Characterization of TRIP6-dependent nasopharyngeal cancer cell migration

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2329-2335

  Fei, Jie ^a   Li, Jihong ^a   Shen, Sunan ^b   Zhou, Weidong ^a  

^a WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Cancer invasion; Cell migration; Nasopharyngeal carcinoma; TRIP6

Indexed keywords

LIM PROTEIN; PROTEIN TYROSINE KINASE; THYROID RECEPTOR INTERACTOR PROTEIN 6; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MUTANT; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TUMOR INVASION; UPREGULATION; WILD TYPE;

EID: 84881474306     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0780-5     Document Type: Article

References (31)

1. Setton J, Wolden S, Caria N, Lee N. Definitive treatment of metastatic nasopharyngeal carcinoma: report of 5 cases with review of literature. Head & neck. 2012;34:753-7.
2. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012;22:233-44.
3. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;79:420-8.
4. Teo P, Leung SF, Yu P, Lee WY, Shiu W. A retrospective comparison between different stage classifications for nasopharyngeal carcinoma. Br J Radiol. 1991;64:901-8.
5. Sham JS, Cheung YK, Chan FL, Choy D. Nasopharyngeal carcinoma: pattern of skeletal metastases. Br J Radiol. 1990;63:202-5.
6. Leung SF, Teo PM, Shiu WW, Tsao SY, Leung TW. Clinical features and management of distant metastases of nasopharyngeal carcinoma. J Otolaryngol. 1991;20:27-9.
7. Yi J, Beckerle MC. The human TRIP6 gene encodes a LIM domain protein and maps to chromosome 7q22, a region associated with tumorigenesis. Genomics. 1998;49:314-6.
8. Murthy KK, Clark K, Fortin Y, Shen SH, Banville D. ZRP-1, a zyxin-related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E. J Biol Chem. 1999;274:20679-87.
9. Cuppen E, van Ham M, Wansink DG, de Leeuw A, Wieringa B, Hendriks W. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL. Eur J Cell Biol. 2000;79:283-93.
10. Petit MM, Crombez KR, Vervenne HB, Weyns N, Van de Ven WJ. The tumor suppressor Scrib selectively interacts with specific members of the zyxin family of proteins. FEBS Lett. 2005;579:5061-8.
11. Beckerle MC. Zyxin: Zinc fingers at sites of cell adhesion. BioEssays. 1997;19:949-57.
12. Petit MM, Mols R, Schoenmakers EF, Mandahl N, Van de Ven WJ. Lpp, the preferred fusion partner gene of hmgic in lipomas, is a novel member of the lim protein gene family. Genomics. 1996;36:118-29.
13. Marie H, Pratt SJ, Betson M, Epple H, Kittler JT, Meek L, et al. The LIM protein Ajuba is recruited to cadherin-dependent cell junctions through an association with alpha-catenin. J Biol Chem. 2003;278:1220-8.
14. Hervy M, Hoffman L, Beckerle MC. From the membrane to the nucleus and back again: Bifunctional focal adhesion proteins. Curr Opin Cell Biol. 2006;18:524-32.
15. Gur'ianova OA, Sablina AA, Chumakov PM. Frolova EI: [Down-regulation of TRIP6 expression induces actin cytoskeleton rearrangements in human carcinoma cell lines]. Molekuliarnaia biologiia. 2005;39:905-9.
16. Xu J, Lai YJ, Lin WC, Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem. 2004;279:10459-68.
17. Huggins CJ, Andrulis IL. Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers. Cancer Lett. 2008;267:55-66.
18. Li L, Bin LH, Li F, Liu Y, Chen D, Zhai Z, et al. TRIP6 is a RIP2-associated common signaling component of multiple NF-kappaB activation pathways. Journal of cell science. 2005;118:555-63.
19. Behrens J, Weidner KM, Frixen UH, Schipper JH, Sachs M, Arakaki N, et al. The role of E-cadherin and scatter factor in tumor invasion and cell motility. EXS. 1991;59:109-26.
20. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 1996;15:507-25.
21. Lin VT, Lin FT. Trip6: An adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity. Cell Signal. 2011;23:1691-7.
22. Lai YJ, Lin WC, Lin FT. PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J Biol Chem. 2007;282:24381-7.
23. Lai YJ, Chen CS, Lin WC. Lin FT: c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol Cell Biol. 2005;25:5859-68.
24. Chong VF, Ong CK. Nasopharyngeal carcinoma. Eur J Radiol. 2008;66:437-47.
25. Arango BA, Castrellon AB, Perez CA, Raez LE, Santos ES. Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev Anticancer Ther. 2010;10:377-86.
26. 26 Lin VT, Lin VY, Lai YJ, Chen CS, Liu K, Lin WC, Lin FT (2013) TRIP6 regulates p27KIP1 to promote tumorigenesis. Mol Cell Biol
27. Chastre E, Abdessamad M, Kruglov A, Bruyneel E, Bracke M, Di Gioia Y, et al. TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2009;23:916-28.
28. Sirvent A, Benistant C, Pannequin J, Veracini L, Simon V, Bourgaux JF, et al. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene. 2010;29:1303-15.
29. Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem. 2003;278:6936-41.
30. Gomes EG, Connelly SF, Summy JM (2013) Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo. Pancreas
31. Nam HJ, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013;12:16-26.